EUVIMED · CrossrefJournal
Hormone Research in Paediatrics
ISSN 1663-2818 · S. Karger AG
Latest articles
Isolated Hyperchlorhidrosis Caused by Novel Biallelic CA12 Variants Mimicking Pseudohypoaldosteronism
Consensus Without the Difficult Questions: Clinical and Methodological Reflections on the International Idiopathic Short Stature Delphi Statements
Predominant Mineralocorticoid Deficiency in ZNRF3-Related Adrenal Hypoplasia Congenita: A case report
Artificial Intelligence in Paediatric Endocrinology: A Narrative Review from the Perspective of Early-career Clinicians and Researchers
When Less is More: A Physiology-Driven Approach to a 17-Hydroxylase Deficiency Case Series
O-01: Nationwide incidence trends of type 1 diabetes in children and adolescents in Bangladesh: a 15-year multi centre Population-Based study (2010–2024)
O-02: Marked heterogeneity in type 2 diabetes prevalence across disaggregated Asian American and pacific islander adolescents and young adults in an integrated health system: the PAPAYA study
O-03: Changing patterns of type 1 diabetes in South Asian children and adolescents: trends in deaths, DALYs, and prevalence from GBD 2000–2023
O-04: Evidence of clinically meaningful subclusters of pediatric patients with T1D identified using unsupervised clustering analysis: preliminary findings from the everyone study
O-05: Index60 as a predictor of type 1 diabetes progression in first-degree relatives with positive islet autoantibodies
O-06: Schools as screen points for early-stage type 1 diabetes – EDENT1FI in Portugal
O-07: Nationwide type 1 diabetes screening in Czechia within the EDENT1FI study: 1% of the pediatric population screened
O-08: Autoantibody screening in First-Degree relatives of children with type 1 diabetes in a sibling-dominant cohort: a multicenter study on prevalence, determinants, and Post-Screening parent–child anxiety
O-09: Diagnostic performance of CGM to identify stage 2 and stage 3 type 1 diabetes in the finnish DIPP-study
O-10: Incidence of diabetes in children and adolescents in Dhaka district, Bangladesh: a Population-Based study (2019-2024)
O-11: Once-Weekly insulin efsitora achieves comparable A1C reduction to daily insulin therapy
O-12: Real-World experiences with teplizumab in clinical practice: perspectives from US pediatric endocrinologists
O-13: Teplizumab (TPZ) in pediatric type 1 diabetes (T1D): Real-World screening, treatment, and disease management – TEPLI-REAL study
O-14: INHALE-1st: inhaled insulin safety and efficacy in youth with Newly-Diagnosed type 1 diabetes
O-15: Heterogeneity of cystic fibrosis related diabetes in the pediatric population in Poland: data from a multicenter Cross-Sectional study
O-16: Screening for insulin resistance in paediatric type 1 diabetes: a pilot insulin-anthropometric model
O-17: GLP-1 – C-peptide lag reveals altered incretin – β-cell coupling during MMTT in GCK, HNF1A, HNF4A diabetes patients
O-18: Assessment of the impact of elexacaftor/tezacaftor/ivacaftor (ETI) on glucose metabolism in cystic fibrosis patients
O-19: GLP-1 receptor agonists in Wolfram syndrome: clinical experience from a pediatric case series
O-20: Regulation of unannounced meals by a closed loop system in adolescents with type 1 diabetes; a multicentre, open-label, randomised, non inferiority trial in real life
O-21: “We can achieve it together”: increased utilization of insulin pumps and improving health equity among youth with type 1 diabetes: a unique, multi-disciplinary quality improvement initiative
O-22: Finding the 90-second anchor: defining the engagement sweet spot for pediatric diabetes (T1D) video education through Duration-Retention analysis
O-23: Graded-evidence reasoning AI with calculators and education — a deterministic, compounding-evidence AI diabetes educator for type 1 diabetes, validated via 1.5 million patient-days of real-world data
O-24: Glycemic outcomes and automated insulin delivery in over 140 000 children with type 1 diabetes: a 5-year longitudinal follow-up from paediatric diabetes registries
O-25: AI-integrated biosensor wearables for Real-Time monitoring and personalized risk mitigation in adolescents with type 1 diabetes and early diabetic kidney disease
Volumes
2026 · 6202025 · 1442024 · 1722023 · 1062022 · 952021 · 682020 · 922019 · 1232018 · 1312017 · 1312016 · 1362015 · 1382014 · 1372013 · 1422012 · 1392011 · 2072010 · 1482009 · 1952008 · 1292007 · 2382006 · 1672005 · 1562004 · 1712003 · 1952002 · 1832001 · 1662000 · 1861999 · 1801998 · 1681997 · 181996 · 81995 · 61994 · 61992 · 31991 · 21990 · 41989 · 51972 · 341971 · 311970 · 29
EUVIMED